Publikationen 2025

Auth J, Müller F, Völkl S, Bayerl N, Distler JHW, Tur C, Raimondo MG, Chenguiti Fakhouri S, Atzinger A, Coppers B, Eckstein M, Liphardt AM, Bäuerle T, Tascilar K, Aigner M, Kretschmann S, Wirsching A, Taubmann J, Hagen M, Györfi AH, Kharboutli S, Krickau T, Dees C, Spörl S, Rothe T, Harrer T, Bozec A, Grieshaber-Bouyer R, Fuchs F, Kuwert T, Berking C, Horch RE, Uder M, Mackensen A, Schett G, Bergmann C: (2025) CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol.. 2025;7(2): e83-e93
Mougiakakos D, Sengupta R, Gold R, Schroers R, Haghikia A, Lorente M, Pendleton M, Register A, Heesen C, Kröger N, Schett G, Mackensen A, Podoll A, Gutman J, Furie R, Bayer R, Distler JHW, Dietrich S, Krönke G, Bullinger L, Walker K: (2025) Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders. Cytotherapy. 2025;27(2): 236-246
Unglaub JM, Schlenk RF, Middeke JM, Krause SW, Kraus S, Einsele H, Kramer M, Zukunft S, Kauer J, Renders S, Katelari E, Schliemann C, Pabst C, Luft T, Dreger P, Röllig C, Bornhäuser M, Müller-Tidow C, Sauer T: (2025) Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML. Blood Adv. 2025;9(2): 375-385
Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M: (2025) Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia. J Clin Oncol. 2025;43(1): 65-74
Westermann L, Diergaarde B, Heidegger S, Poeck H, Szczepański MJ, Reichert TE, Spoerl S, Whiteside TL, Spoerl S, Ludwig N: (2025) Expression of vesiculation-related genes is associated with a tumor-promoting microenvironment: a pan-cancer analysis. Clin Transl Oncol. 2025;():
Katsivelos N, Spyrou N, Weber D, Vasova I, Ayuk F, Choe H, Hogan W, DeFilipp Z, Qayed M, Etra AM, Sandhu K, Kraus S, Olson T, Hexner E, Aguayo-Hiraldo P, Reshef R, Ullrich E, Schechter T, Kitko C, Chanswangphuwana C, Merli P, Akahoshi Y, Baez J, Eng G, Beheshti R, Kowalyk S, Morales G, Louloudis IE, Young R, Holler E, Nakamura R, Ferrara JLM, Levine JE: (2025) Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group. Transplant Cell Ther. 2025;31(1): 10.e1-10.e9
Schroeder T, Flossdorf S, Schuh C, Pabst C, Stadler M, Schetelig J, Wehr C, Stelljes M, Sala E, Burchert A, Winkler J, Reinhardt HC, Kröger N, Fleischhauer K, Rautenberg C: (2025) Outcome of Patients With IDH-Mutated AML Following Allogeneic Stem Cell Transplantation-A Retrospective Analysis on Behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRST. Transplant Cell Ther. 2025;():
Dingfelder J, Taubmann J, von Heydebrand F, Aigner M, Bergmann C, Knitza J, Park S, Cheng JK, Van Blarcom T, Schett G, Mackensen A, Lutzny-Geier G: (2025) Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients. Int J Mol Sci. 2025;26(2):
Tasbihi K, Bruns H: (2025) Selinexor's Immunomodulatory Impact in Advancing Multiple Myeloma Treatment. Cells. 2025;14(6):
Schmidt KG, Geißler P, Schuster EM, Schülein C, Harrer EG, Schönau V, Luber M, Spriewald B, Steininger P, Bergmann S, Ensser A, Schober K, Nganou-Makamdop K, Harrer T: (2025) Coronavirus replicase epitopes induce cross-reactive CD8 T cell responses in SARS-CoV-2-naive people with HIV-1. iScience. 2025;28(3):
Falck D, Sokolova MV, Koeleman CAM, Irumva V, Kirchner P, Schulz SR, Schmidt KG, Harrer T, Ekici AB, Spriewald B, Schett G, Wuhrer M, Herrmann M, Steffen U: (2025) IgA displays site- and subclass-specific glycoform differences despite equal glycoenzyme expression. Cell Commun Signal. 2025;23(1):
Beck M, Blumenberg V, Bücklein VL, Bundschuh RA, Harrer DC, Hirschbühl K, Jung J, Kunz WG, Menhart K, Winkelmann M, Yakushev I, Illert AL, Eckstein M, Völkl S, Claus R, Hansmann L, Hecker JS, Kuwert T, Mackensen A, Subklewe M, Hellwig D, Müller F: (2025) Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma. EJNMMI Res. 2025;15(1):
Scholz JK, Stabel L, Schwingen NR, Knopf J, Flatt AS, Bäuerle T, Krause S, Waibel H, Leppkes M, Kortüm KM, Einsele H, Mackensen A, Herrmann M, Völkl S, Müller F: (2025) One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy. Haematologica. 2025;():
Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf TH, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, Niemann D, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JMM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C: (2025) Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia. Blood Adv. 2025;9(6): 1392-1404
Stasik S, Eckardt JN, Röllig C, Baldus CD, Platzbecker U, Serve H, Müller-Tidow C, Schäfer-Eckart K, Kaufmann M, Krause SW, Sauer T, Hänel M, Neubauer A, Ehninger G, Bornhäuser M, Schetelig J, Middeke JM, Thiede C, Study Alliance Leukemia (SAL): (2025) The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML. Br J Haematol. 2025;():
Esse J, Träger J, Steininger P, Bihlmaier K, Fürst J, Bardonicsek-Depnering Z, Naumann-Bartsch N, Morhart P, Castellanos I, Krause SW, Herbst L, Strauß R, Chada M, Korn K, Valenza G, Teschner D, Bogdan C, Held J: (2025) Metagenomic analysis of microbial cell-free DNA from plasma of patients with suspected infections: performance and therapeutic impact in clinical routine. Clin Microbiol Infect. 2025;():
Knabe R, Muller P, Schliemann C, Hanoun M, Unglaub JM, Weinbergerová B, Mayer J, Krekeler C, Krause SW, Kaufmann M, Kraus S, Steffen B, Modemann F, Subklewe M, Bücklein VL, Kunz WG, Rudelius M, von Bergwelt-Baildon M, Gutmair K, Hoster E, Herold T, Röllig C, Spiekermann K: (2025) Gastrointestinal toxicity of Gemtuzumab Ozogamicin: Real-life data from the AMLCG, SAL and CELL study groups. Blood Adv. 2025;():
Rautenberg C, Middeke JM, Röllig C, Stelljes M, Gaidzik V, Kriege O, Verbeek M, Koch K, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Wass M, Heuser M, Fransecky L, Chemnitz J, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Kobbe G, Jäger PS, Alakel N, von Bonin M, Sockel K, Hanoun M, Platzbecker U, Holderried TAW, Morgner A, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Flossdorf S, Schroeder T, Stölzel F: (2025) Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients. Blood Cancer J. 2025;15(1):
Taubmann J, Mueller F, Mutlu MY, Voelkl S, Aigner M, Bozec A, Mackensen A, Grieshaber-Bouyer R, Schett G: (2025) Correction to CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2025;77(3):
Schubart C, Tögel L, Carta MG, Hetzner P, Helbig L, Zaglas C, Ziegler M, Stöhr R, Hölsken A, Hoyer J, Ferrazzi F, Neufert C, Lettmaier S, Pavel M, Golcher H, Mueller SK, Fuchs F, Schulmeyer CE, Beckmann MW, Wullich B, Agaimy A, Reis A, Hartmann A, Meidenbauer N, Spoerl S, Haller F, Moskalev EA: (2025) Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD? Int J Cancer. 2025;():

Schriftgröße anpassen

Publikationen 2025

Publikationen 2025

Notfall

Notfallinformationen UKER

Patienten & Besucher

Ärzte & Zuweiser

Forschung

Lehre